Clinical role of serum S1P in the early diagnosis of colorectal cancer

doi:10.3969/j.issn.1673-8640.2023.04.002

Abstract

Abstract:

Objective To investigate the clinical role of serum sphingosine-1-phosphate（S1P） in the early diagnosis of colorectal cancer. Methods A total of 42 patients with colorectal cancer and 30 patients with colorectal benign lesions were enrolled. Totally，38 healthy subjects were enrolled as healthy control group. The clinicopathologic data of colorectal cancer group were collected. Serum S1P levels were determined. Receiver operating characteristic（ROC） curve was used to evaluate the diagnostic efficacy of S1P single and combined determinations with carcinoembryonic antigen（CEA） and carbohydrate antigen 19-9（CA19-9）in colorectal cancer. Results Serum S1P level in colorectal cancer group was higher than those in colorectal benign lesion group and healthy control group（P<0.05，P<0.001）. Serum S1P level of stage Ⅰ to Ⅱ colorectal cancer group was higher than those of stage Ⅲ to Ⅳ colorectal cancer group，colorectal benign lesion group and healthy control group（P<0.05，P<0.05，P<0.001）. Serum S1P level in colorectal benign lesion group was higher than that in healthy control group（P<0.001）. Serum S1P levels in colorectal cancer patients with lymph metastasis were lower than those without lymph metastasis（P<0.05），but there was no statistical significance in serum S1P levels among patients with other clinicopathologic characteristics（P>0.05）. ROC curve analysis results showed that，using healthy control group as control，the areas under curves（AUC） of serum S1P，CEA and CA19-9 for the diagnosis of colorectal cancer were 0.924，0.701，0.579 and 0.943，respectively. The AUC for the diagnosis of stage Ⅰ to Ⅱ colorectal cancer were 0.944，0.663，0.611 and 0.955，respectively，and the AUC for the diagnosis of single or simultaneous negative CEA and CA19-9 colorectal cancer were 0.919，0.628，0.526 and 0.932，respectively. Using colorectal benign lesion group as control，the AUC of the single and combined determinations of the 3 indicators were 0.655，0.720，0.582 and 0.787，respectively. Conclusions S1P may be a biomarker for the diagnosis of early colorectal cancer.

Key words: Sphingosine-1-phosphate, Colorectal cancer, Carcinoembryonic antigen, Carbohydrate antigen 19-9

CLC Number:

R446.1

JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer[J]. Laboratory Medicine, 2023, 38(4): 307-312.

Figures/Tables 9

References 17.

1.	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI URL
2.	SMITH R A, FEDEWA S, SIEGEL R. Early colorectal cancer detection-current and evolving challenges in evidence,guidelines,policy,and practices[J]. Adv Cancer Res, 2021, 151:69-107.
3.	VAN DOORN R, VAN HORSSEN J, VERZIJL D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions[J]. Glia, 2010, 58(12):1465-1476. DOI PMID
4.	SÁNCHEZ D I, GONZÁLEZ-FERNÁNDEZ B, SAN-MIGUEL B, et al. Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma[J]. J Pineal Res, 2017, 62(1).
5.	SHIDA D, INOUE S, YOSHIDA Y, et al. Sphingosine kinase 1 is upregulated with lysophosphatidic acid receptor 2 in human colorectal cancer[J]. World J Gastroenterol, 2016, 22(8):2503-2511. DOI URL
6.	SATTAR R S A, SUMI M P, NIMISHA, et al. S1P signaling,its interactions and cross-talks with other partners and therapeutic importance in colorectal cancer[J]. Cell Signal, 2021, 86:110080. DOI URL
7.	BENAMOUZIG R, BARRÉ S, SAURIN J C, et al. Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals[J]. Therap Adv Gastroenterol, 2021, 14:17562848211002359.
8.	IMPERIALE T F, RANSDOHOFF D F, ITZKOWITZ S H, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14):1287-1297. DOI URL
9.	陈思, 刘华, 刘鷖雯, 等. 血清HER-2、CD44联合检测在结直肠癌中的临床价值[J]. 检验医学, 2022, 37(4):336-341.
10.	AHLQUIST D A, TAYLOR W R, MAHONEY D W, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia[J]. Clin Gastroenterol Hepatol, 2012, 10(3):272-277. e1. DOI URL
11.	SHAUKAT A, LEVIN T R. Current and future colorectal cancer screening strategies[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(8):521-531. DOI PMID
12.	SUKOCHEVA O A, FURUYA H, NG M L, et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers:a novel therapeutic target[J]. Pharmacol Ther, 2020, 207:107464. DOI URL
13.	ANDRIEU G, LEDOUX A, BRANKA S, et al. Sphingosine 1-phosphate signaling through its receptor S1P₅ promotes chromosome segregation and mitotic progression[J]. Sci Signal, 2017, 10(472):eaah4007. DOI URL
14.	PYNE N J, PYNE S. Recent advances in the role of sphingosine 1-phosphate in cancer[J]. FEBS Lett, 2020, 594(22):3583-3601. DOI URL
15.	GU X, JIANG Y, XUE W, et al. SPNS2 promotes the malignancy of colorectal cancer cells via regulating Akt and ERK pathway[J]. Clin Exp Pharmacol Physiol, 2019, 46(9):861-871. DOI URL
16.	YAN J, CHEN Y, WU Q, et al. Expression of sphingosine-1-phosphate receptor 2 is correlated with migration and invasion of human colon cancer cells:a preliminary clinical study[J]. Oncol Lett, 2022, 24(1):241. DOI URL
17.	NUNES J, NAYMARK M, SAUER L, et al. Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection[J]. Br J Cancer, 2012, 106(5):909-915. DOI

组别	例数	S1P/（nmol/L）
结直肠癌组	42	721.15（619.25~908.30）^*#
Ⅰ~Ⅱ期结直肠癌组	22	840.80（708.47~984.95）^*#△
Ⅲ~Ⅳ期结直肠癌组	18	638.65（541.80~752.38）^*
良性病变组	30	628.40（325.23~828.30）^*
正常对照组	38	295.80（233.58~451.80）

组别	例数	S1P/（nmol/L）
结直肠癌组	42	721.15（619.25~908.30）^*#
Ⅰ~Ⅱ期结直肠癌组	22	840.80（708.47~984.95）^*#△
Ⅲ~Ⅳ期结直肠癌组	18	638.65（541.80~752.38）^*
良性病变组	30	628.40（325.23~828.30）^*
正常对照组	38	295.80（233.58~451.80）

临床病理特征	例数	S1P/（nmol/L）
年龄
<61岁	17	775.80（575.80~973.00）
≥61岁	25	709.80（625.65~864.80）
Z值		187.500
P值		0.522
性别
男	28	785.65（628.23~968.45）
女	14	661.15（478.63~809.08）
Z值		120.500
P值		0.053
肿瘤大小
<10 cm	13	831.80（699.15~1 067.80）
≥10 cm	21	695.50（575.80~862.80）
Z值		3.029
P值		0.220
TNM分期
Ⅰ~Ⅱ 期	22	840.80（708.47~984.95）
Ⅲ~Ⅳ期	18	638.65（541.80~752.38）
Z值		7.739
P值		0.029
淋巴转移
无	26	823.80（670.83~984.95）
有	12	625.80（471.45~706.23）
Z值		9.832
P值		0.007
神经侵犯
无	10	719.80（529.60~850.80）
有	27	713.80（625.80~968.00）
Z值		1.749
P值		0.417
脉管侵犯
无	20	758.65（606.75~886.80）
有	17	709.80（588.80~907.80）
Z值		1.349
P值		0.510
Ras基因型
野生型	20	719.15（629.58~848.30）
突变型	14	832.80（625.80~1 041.30）
Z值		2.049
P值		0.359

临床病理特征	例数	S1P/（nmol/L）
年龄
<61岁	17	775.80（575.80~973.00）
≥61岁	25	709.80（625.65~864.80）
Z值		187.500
P值		0.522
性别
男	28	785.65（628.23~968.45）
女	14	661.15（478.63~809.08）
Z值		120.500
P值		0.053
肿瘤大小
<10 cm	13	831.80（699.15~1 067.80）
≥10 cm	21	695.50（575.80~862.80）
Z值		3.029
P值		0.220
TNM分期
Ⅰ~Ⅱ 期	22	840.80（708.47~984.95）
Ⅲ~Ⅳ期	18	638.65（541.80~752.38）
Z值		7.739
P值		0.029
淋巴转移
无	26	823.80（670.83~984.95）
有	12	625.80（471.45~706.23）
Z值		9.832
P值		0.007
神经侵犯
无	10	719.80（529.60~850.80）
有	27	713.80（625.80~968.00）
Z值		1.749
P值		0.417
脉管侵犯
无	20	758.65（606.75~886.80）
有	17	709.80（588.80~907.80）
Z值		1.349
P值		0.510
Ras基因型
野生型	20	719.15（629.58~848.30）
突变型	14	832.80（625.80~1 041.30）
Z值		2.049
P值		0.359

项目	AUC（95%可信区间）	最佳临界值	敏感性/%	特异性/%	误诊率/%	漏诊率/%	Youden指数
S1P	0.924（0.861~0.986）	436.90 nmol/L	100.00	76.30	23.70	0.00	0.763
CEA	0.701（0.584~0.818）	3.10 ng/mL	57.50	81.60	18.40	42.50	0.391
CA19-9	0.579（0.435~0.723）	16.30 U/mL	42.50	100.00	0.00	57.50	0.425
联合检测	0.943（0.895~0.990）	0.02	90.00	89.50	10.50	10.00	0.795